HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The treatment of psoriasis with 0.1% domoprednate (a D-homocorticosteroid) and 0.1% betamethasone valerate ointment. A double-blind, randomized trial.

Abstract
In 85 patients with psoriasis vulgaris the efficacy and tolerance of domoprednate and betamethasone valerate were studied in a double-blind, randomized trial lasting 4 weeks. Complete or satisfactory remission was obtained in 36% in the domoprednate group and in 53% in the betamethasone group. This difference is not statistically significant (p greater than 0.10). 3 patients on each treatment experienced some local irritation. No laboratory abnormalities were found during the study.
AuthorsJ V Christiansen, E Foged, P Holm, A S Jørgensen, F Reymann
JournalDermatologica (Dermatologica) Vol. 170 Issue 4 Pg. 195-8 ( 1985) ISSN: 0011-9075 [Print] Switzerland
PMID3888709 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Ointments
  • Pregnadienes
  • domoprednate
  • Betamethasone
  • Betamethasone Valerate
Topics
  • Adolescent
  • Adult
  • Aged
  • Betamethasone (analogs & derivatives)
  • Betamethasone Valerate (administration & dosage, adverse effects)
  • Clinical Trials as Topic
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Ointments
  • Pregnadienes (administration & dosage, adverse effects)
  • Psoriasis (drug therapy)
  • Random Allocation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: